(Total Views: 477)
Posted On: 05/17/2021 6:00:23 PM
Post# of 148899
Seems to me the FDA article is an extremely risky, foolish, unwise, and a "doubling-down" write-up, and that's an understatement. A sign of desperation and of powerful cohercion. A clear indicator of outside corrupt pressure.
CD10 actually achieved "Clinical Signficance" for its Primary Endpoint, and "Statistical Significance" for the Secondary Endpoint NEWS2.
FDA today says....
In the smaller study that CytoDyn conducted in patients with mild-to-moderate COVID-19 disease (CD10), there was no observed effect of the drug on the study’s primary endpoint or on any of the secondary endpoints.
CD10 actually achieved "Clinical Signficance" for its Primary Endpoint, and "Statistical Significance" for the Secondary Endpoint NEWS2.
FDA today says....
In the smaller study that CytoDyn conducted in patients with mild-to-moderate COVID-19 disease (CD10), there was no observed effect of the drug on the study’s primary endpoint or on any of the secondary endpoints.
(7)
(0)Scroll down for more posts ▼
